Comparative Pharmacology
Head-to-head clinical analysis: GRIFULVIN V versus GRISACTIN ULTRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRIFULVIN V versus GRISACTIN ULTRA.
GRIFULVIN V vs GRISACTIN ULTRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubule-associated proteins and disrupts fungal mitotic spindle formation, thereby inhibiting fungal cell division. It also interferes with fungal nucleic acid synthesis.
Griseofulvin binds to tubulin and disrupts microtubule function, inhibiting fungal cell division and nucleic acid synthesis.
500 mg orally once daily (non-microsize formulation) or 250 mg twice daily; typical duration is 4-8 weeks for tinea capitis, 2-6 weeks for tinea corporis, 4-6 weeks for tinea pedis.
500 mg orally once daily or 250 mg orally twice daily; for severe infections, 500 mg twice daily or 250 mg three times daily. Maximum daily dose: 1 g. Administer with or after meals.
None Documented
None Documented
Terminal half-life: 9–24 hours. Clinical context: Steady-state achieved in 2–5 days; prolonged in hepatic impairment.
Terminal elimination half-life ranges from 6.5 to 9 hours (mean ~7.5 hours) in patients with normal hepatic function; prolonged in hepatic impairment.
Renal (1% unchanged), fecal (33% as metabolites), biliary (minor). Extensive hepatic metabolism; <1% excreted unchanged in urine.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine; approximately 30-50% of a dose is eliminated in feces as metabolites, with minor biliary excretion.
Category C
Category C
Antifungal
Antifungal